Navigation Links
Phase Holographic Imaging and University of California, San Francisco Commence Collaboration on Skin Cancer Research
Date:10/26/2015

SAN FRANCISCO and LUND, Sweden, October 26, 2015 /PRNewswire/ --

University of California, San Francisco (UCSF) and Phase Holographic Imaging (PHI) have begun their collaboration agreement to accelerate on-going skin cancer research utilizing PHI's proprietary label-free holographic imaging cytometry technology. The newly released version of the HoloMonitor® M4 has been delivered to UCSF. The program will focus on establishing the best practices and validating the most useful HoloMonitor M4 parameters for simultaneous detection of changes in proliferation, cell death and motility in primary human melanomas and cultured melanocytes.

The collaboration will be led by Robert Judson, PhD, UCSF Sandler Faculty Fellow and NIH Early Independence Award Fellow, whose interests concentrate on developing novel strategies for early detection of melanoma. According to the American Cancer Society, melanoma accounts for less than 2% of skin cancers but contributes to a large majority of skin cancer deaths. The incidence of melanoma is on the rise with over 70 0000 new diagnoses and close to 10 000 related deaths expected in the US in 2015.

"Our mission is to develop an understanding of human melanoma by engineering its progression in vitro and use this knowledge to drive discoveries in prevention, diagnostics and treatment of this deadly disease," said Dr. Judson and continued:

"Using techniques in molecular biology, biochemistry, genetics, imaging, and tissue culture, we are probing a variety of intrinsic and extrinsic factors for their ability to render melanocytes susceptible to malignant transformation. The original purchase of PHI's HoloMonitor M4 instrument in 2014 was essential for our ability to detect subtle changes in a variety of oncogenic phenotypes with single cell resolution within larger populations. As a label-free, non-toxic imaging system, the M4 provides us the means to begin investigating the immediate reaction of melanoma cells to acute environmental and genetic stimuli. The new instrument equipped with motorized stage and advanced data acquisition software will bring additional benefits of automated walk-away analysis and higher throughput." 

As a result of this collaboration UCSF and PHI expect to validate novel label-free cellular assays, develop best HoloMonitor technology practices and apply them to testing of therapeutic agents in primary and genetically engineered melanoma cell lines.

"We are excited to deliver our new HoloMonitor instrumentation to the lab recently launched by Dr. Judson and begin our collaboration by providing support of novel research programs in the study of skin cancer. We view the collaboration with UCSF as an exciting first step towards expanding our Centers of Excellence in Holographic Imaging Cytometry to the San Francisco area," said CEO Peter Egelberg.

  • PHI Centers of Excellence 

A Center of Excellence is an application development hub and educational resource providing training programs and information sharing platforms for scientists using PHI's HoloMonitor technology. PHI's Centers of Excellence are designed to create technology visibility in life science hot-spots such as Boston, London, Basel, Heidelberg, San Diego, San Francisco and Tokyo. The first Center of Excellence has been established at Northeastern University in Boston.

Links 

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies. 

  • UC Disclaimer  

The information stated above was prepared by Phase Holographic Imaging (PHI) and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of PHI, or any of its products, by The Regents of the University of California, its officers, agents and employees. 

Web: http://www.phiab.se

 


'/>"/>
SOURCE University of California, San Francisco (UCSF) and Phase Holographic Imaging (PHI)
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
2. Self-assembled nanostructures enable a low-power phase-change memory for mobile electronic devices
3. Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology
4. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
5. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
6. irisnote Announces Successful Conclusion of Beta Test Phase
7. Risk Assessment and Mitigation in Phase I Trials in High Risk Compounds: A Continuously Developing Process, new life science webinar hosted by Xtalks
8. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
9. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
10. St. Mary Completes Phase 2 of Its Emergency Department and Trauma Center Expansion
11. Gene Therapy Developed for ALS Treatment: New Biotech Company Neuralgene Enters Evaluation Phase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions ... over 5.5 million people each year. Especially those living in larger cities are affected ... based in one of the most pollution-affected countries globally - decided to take action. ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):